Literature DB >> 17341266

An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies.

Dolores Bobadilla1, Elmon L Enriquez, Georgina Alvarez, Popsie Gaytan, David Smith, Marilyn L Slovak.   

Abstract

Chromosome rearrangements involving band 3q26.2 are associated with myeloid malignancies, aberrant expression of the human ecotropic virus integration site-1 (EVI1) gene, an unfavourable prognosis and an aggressive clinical course. The 3q26.2 rearrangements are characteristically heterogeneous and typically difficult to detect in poor quality metaphases. To develop a dual-colour fluorescence in situ hybridisation (FISH) assay for the detection of 3q26.2/EVI1 aberrations, a series of 10 BAC clones corresponding to the EVI1 gene region were systematically evaluated and narrowed down to two probe sets; one probe set encompassed the EVI1 gene extending centromeric, while the second probe set covered the EVI1 gene and extends telomeric. Both probe sets were evaluated on 35 patient samples with cytogenetically defined 3q26.2 rearrangements collected at various treatment time points, the inv(3)(q21q26.2) Kasumi-4 cell line, and 10 known negative samples. The two-probe set strategy identified all samples, despite the vast breakpoint heterogeneity observed. In samples from acute myeloid leukaemia and myelodysplastic syndrome cases, the majority of inversion breakpoints were 3' to EVI1 whereas 3q26.2 translocation breakpoints frequently mapped 5' to EVI1. However, two 3q26.2 translocation samples had breakpoints 3' to EVI1. Most inv(3q) chronic myeloid leukaemia samples showed breakpoints within the EVI1 gene. This study demonstrated that, despite the extensive breakpoint heterogeneity observed with 3q26.2 aberrations, this FISH strategy is effective for the detection of 3q26.2 abnormalities in myeloid malignancies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17341266     DOI: 10.1111/j.1365-2141.2007.06505.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Therapy-related myelodysplastic syndrome: a case study.

Authors:  Masahiro Manabe; Katsuya Wada; Dai Momose; Yasuyoshi Sugano; Masayuki Hino; Takahisa Yamane; Eiwa Ishida; Ki-Ryang Koh
Journal:  Am J Blood Res       Date:  2015-12-25

2.  Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.

Authors:  Anjali S Advani; Holly M Gundacker; Olga Sala-Torra; Jerald P Radich; Raymond Lai; Marilyn L Slovak; Jeffrey E Lancet; Steve E Coutre; Robert K Stuart; Martha P Mims; Patrick J Stiff; Frederick R Appelbaum
Journal:  Br J Haematol       Date:  2010-12       Impact factor: 6.998

3.  Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities.

Authors:  Arash Ronaghy; Shimin Hu; Zhenya Tang; Wei Wang; Guilin Tang; Sanam Loghavi; Shaoying Li; Beenu Thakral; L Jeffrey Medeiros; Tariq Muzzafar
Journal:  Mod Pathol       Date:  2020-10-27       Impact factor: 7.842

4.  Assessing karyotype precision by microarray-based comparative genomic hybridization in the myelodysplastic/myeloproliferative syndromes.

Authors:  Marilyn L Slovak; David D Smith; Victoria Bedell; Ya-Hsuan Hsu; Margaret O'Donnell; Stephen J Forman; Karl Gaal; Lisa McDaniel; Roger Schultz; Blake C Ballif; Lisa G Shaffer
Journal:  Mol Cytogenet       Date:  2010-11-15       Impact factor: 2.009

5.  Detection of RUNX1-MECOM fusion gene and t(3;21) in a very elderly patient having acute myeloid leukemia with myelodysplasia-related changes.

Authors:  John Jeongseok Yang; Sun Young Cho; Jin-Tae Suh; Hee Joo Lee; Woo-In Lee; Hwi-Joong Yoon; Sun Kyung Baek; Tae Sung Park
Journal:  Ann Lab Med       Date:  2012-08-13       Impact factor: 3.464

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.